March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.

March Biosciences

Sarah Hein

Steven Lehmann

Alice Bexon

Peter Olagunju

Federica Giordano

Doris Sanchez

Max Mamonkin

The Clinical Development and Strategy team at March Biosciences spearheads the design and execution of clinical trials to advance innovative cell therapies for hematological malignancies. This team, comprising experts in clinical development, regulatory affairs, and oncology, collaborates closely to ensure compliance with regulatory standards, optimize trial protocols, and drive strategic decisions that enhance the potential of novel treatments in addressing high-challenge cancers.

Clinical Development and Strategy

Leadership Team

Clinical Development and Strategy

About

Team members

Other teams at March Biosciences

Leadership Team